Psoriasis as a disease associated with the immune system disorders

Central-European Journal of Immunology

Volumn 38, Issue 1, 2013, Pages 129-133

  Chomiczewska Skóra, Dorota ^a   Trznadel Grodzka, Ewa ^b   Rotsztejn, Helena ^b  

^a NOFER INSTITUTE OF OCCUPATIONAL MEDICINE   (Poland)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Cytokines; Dendritic cells; Lymphocytes; Psoriasis

Indexed keywords

CD45RO ANTIGEN; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR6; CHEMOKINE RECEPTOR CXCR5; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GAMMA INTERFERON; HEAT SHOCK PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 20; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 6; INTERLEUKIN 8; KERATINOCYTE GROWTH FACTOR; RANTES; TUMOR NECROSIS FACTOR ALPHA; VASCULAR ADHESION PROTEIN 1; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN;

ANTIGEN PRESENTING CELL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOKINE RELEASE; DENDRITIC CELL; DISEASE ASSOCIATION; HUMAN; IMMUNOPATHOLOGY; KERATINOCYTE; LANGERHANS CELL; MACROPHAGE; MEMORY T LYMPHOCYTE; MONOCYTE; NATURAL KILLER T CELL; NEUTROPHIL; PROTEIN EXPRESSION; PSORIASIS; REGULATORY T LYMPHOCYTE; REVIEW; TH1 CELL; TH17 CELL; TH22 CELL;

EID: 84881330552     PISSN: 14263912     EISSN: 16444124     Source Type: Journal    
DOI: 10.5114/ceji.2013.34370     Document Type: Review

References (53)

1. Kemény L, Ruzicka T, Braun-Falco O (1990): Dithranol: a review of the mechanism of action in the treatment of psoriasis vulgaris. Skin Pharmacol 3: 1-20.
2. Nickoloff BJ, Nestle FO (2004): Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest 113: 1664-1675.
3. Christophers E, Barker JN, Griffiths CE, et al. (2010): The risk of psoriatic arthritis remains constant following initial diagnosis of psoriasis among patients seen in European dermatology clinics. J Eur Acad Dermatol Venereol 24: 548-554.
4. Gottlieb AB, Chao C, Dann F (2008): Psoriasis comorbidities. J Dermatolog Treat 19: 5-21.
5. Gisondi P, Tessari G, Conti A, et al. (2007): Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 157: 68-73.
6. Szponar-Bojda A, Krasowska D, Pietrzak A, Chodorowska G (2012): Metabolic syndrome in psoriasis. Postep Derm Alergol 29: 356-362.
7. Büchau AS, Gallo RL (2007): Innate immunity and antimicrobial defense systems in psoriasis. Clin Dermatol 25: 616-624.
8. Elder JT (2009): Genome-wide association scan yields new insights into the immunopathogenesis of psoriasis. Genes Immun 10: 201-209.
9. Das RP, Jain AK, Ramesh V (2009): Current concepts in the pathogenesis of psoriasis. Indian J Dermatol 54: 7-12.
10. Prinz JC (2010): From bench to bedside - translational research in psoriasis. J Eur Acad Dermatol Venereol 24 (Suppl 6): 1-4.
11. Michalak-Stoma A, Pietrzak A, Szepietowski JC, et al. (2011): Cytokine network in psoriasis revisited. Eur Cytokine Netw 22: 160-168.
12. Nickoloff BJ, Schröder JM, von den Driesch P, et al. (2000): Is psoriasis a T-cell disease? Exp Dermatol 9: 359-375.
13. Rotsztejn H, Zalewska A, Trznadel-Budźko E, et al. (2005): Influence of systemic photochemotherapy on regulatory T cells and selected cytokine production in psoriatic patients - a pilot study. Med Sci Monit 11: CR594-8.
14. Chomiczewska D, Trznadel-Grodzka E, Kaczorowska A, Rotsztejn H (2009): Znaczenie komórek Langerhansa w układzie immunologicznym skóry. Pol Merk Lek XXVI, 153: 173-177.
15. Sabat R, Philipp S, Höflich C, et al. (2007): Immunopathogenesis of psoriasis. Exp Dermatol 16: 779-798.
16. Bos JD, de Rie MA, Teunissen MB, Piskin G (2005): Psoriasis: dysregulation of innate immunity. Br J Dermatol 152: 1098-1107.
17. van de Kerkhof PC (2007): The evolution of the psoriatic lesion. Br J Dermatol 157: 4-15.
18. Adamski Z, Dudziak M, Zakrzewska K (2011): Etanercept in dermatological practice - authors' own experience in the treatment of psoriasis vulgaris and psoriatic arthritis. Postep Derm Alergol 28: 435-441.
19. Eedy DJ, Burrows D, Bridges JM, Jones FG (1990): Clearance of severe psoriasis after allogenic bone marrow transplantation. Br Med J 300: 908.
20. Sanchez AP (2010): Immunopathogenesis of psoriasis. An Bras Dermatol 85: 747-749.
21. Sweeney CM, Tobin AM, Kirby B (2011): Innate immunity in the pathogenesis of psoriasis. Arch Dermatol Res 303: 691-705.
22. Baker BS, Ovigne JM, Powles AV, et al. (2003): Normal keratinocytes express Toll-like receptors (TLRs) 1, 2 and 5: modulation of TLR expression in chronic plaque psoriasis. Br J Dermatol 148: 670-679.
23. Curry JL, Qin JZ, Bonish B, et al. (2003): Innate immune-related receptors in normal and psoriatic skin. Arch Pathol Lab Med 127: 178-186.
24. Pasch M, Bos JD, Asghar SS (1998): Activation of complement in psoriasis. Clin Exp Dermatol 23: 189-192.
25. Gliński W(2009): Antimicrobial peptides in the pathogenesis of psoriasis and atopic dermatitis. Przegl Dermatol 96: 115-120 [article in Polish].
26. Chang EY, Hammerberg C, Fisher G, et al. (1992): T-cell activation is potentiated by cytokines released by lesional psoriatic, but not normal epidermis. Arch Dermatol 128: 1479-1485.
27. Rogalski C, Meyer-Hoffert U, Proksch E, Wiedow O (2002): Human leukocyte elastase induces keratinocyte proliferation in vitro and in vivo. J Invest Dermatol 118: 49-54.
28. Cameron AL, Kirby B, Fei W, Griffiths CE (2002): Natural killer and natural killer-T cells in psoriasis. Arch Dermatol Res 294: 363-369.
29. Cabrijan L, Lipozencić J, Batinac T, et al. (2009): The role of CD4 and CD8 lymphocytes and macrophages in psoriasis vulgaris. Acta Dermatovenerol Croat 17: 162-165.
30. Nedoszytko B, Roszkiewicz J (2007): The role of the subpopulations of dendritic cells in psoriasis. Post Dermatol Alergol 6: 263-270 [article in Polish].
31. Abrams JR, Kelley SL, Hayes E, et al. (2000): Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunogobulin (CTLA4 Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells and endothelial cells. J Exp Med 192: 681-693.
32. Zhou X, Krueger JG, Kao MC, et al. (2003): Novel mechanism of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100-element oligonucleotide array. Physiol Genomics 13: 69-78.
33. Bovenschen HJ, van Vlijmen-Wilems IM, van de Kerkhof PC, van Erp PE (2006): Identification of lesional CD4+ CD25+ Foxp3+ regulatory T cells in psoriasis. Dermatology 213: 111-117.
34. Krueger JG (2002): The immunologic basis for the treatment of psoriasis with new biological agents. J Am Acad Dermatol 46: 1-23.
35. Baker BS, Swain AD, Fry L, Valdimarsson H (1984): Epidermal T lymphocytes and HLA-DR expression in psoriasis. Br J Dermatol 110: 555-564.
36. Bos JD, Hagenaars C, Das PK, et al. (1989): Predominance of "memory" T cells (CD4+, CDw29+) over "naive" T cells (CD4+, CD45R+) in both normal and diseased human skin. Arch Dermatol Res 281: 24-30.
37. Valdimarsson H, Baker BS, Jónsdóttir I, et al. (1995): Psoriasis: a T-cell mediated autoimmune disease induced by streptococcal superantigens? Immunol Today 16: 145-149.
38. Sigmundsdottir H, Sigurgeirsson B, Troye-Blomberg M, et al. (1997): Circulating T-cells of patients with active psoriasis respond to streptococcal M-peptides sharing sequences with human epidermal keratins. Scand J Immunol 45: 688-697.
39. Majewski S, Jablonska S (2003): Possible involvement of epidermodysplasia verruciformis human papillomaviruses in the immunopathogenesis of psoriasis: a proposed hypothesis. Exp Dermatol 12: 721-728.
40. Lee MR, Cooper AJ (2006): Immunopathogenesis of psoriasis. Australas J Dermatol 47: 151-159.
41. Austin LM, Ozawa M, Kikuchi T, et al. (1999): The majority of epidermal T-cells in psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2 and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J Invest Dermatol 115: 752-759.
42. Sugiyama H, Gyulai R, Toichi E, et al. (2005): Dysfunctional blood and target tissue CD4+ CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation. J Immunol 174: 164-173.
43. Lowes MA, Lew W, Krueger JG (2004): Current concepts in the immunopathogenesis of psoriasis. Dermatol Clin 22: 349-369.
44. Coimbra S, Oliveira H, Reis F, et al. (2010): Interleukin (IL)-22, IL-17, IL-23, IL-8, vascular endothelial growth factor and tumour necrosis factor-a levels in patients with psoriasis before, during and after psoralen - ultraviolet A and narrowband ultraviolet B therapy. Br J Dermatol 163: 1282-1290.
45. Ritchlin C, Haas-Smith SA, Hicks D, et al. (1998): Patterns of cytokine production in psoriatic synovium. J Rheumatol 25: 1544-1552.
46. Fujishima S, Watanabe H, Kawaguchi M, et al. (2010): Involvement of IL-17F via the induction of IL-6 in psoriasis. Arch Dermatol Res 302: 499-505.
47. Arican O, Aral M, Sasmaz S, Ciragil P (2005): Serum levels of TNF-α, IFN-γ, IL-6, IL-8, IL-12, IL-17 and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm 5: 273-279.
48. Menter A (2009): The status of biologic therapies in the treatment of moderate to severe psoriasis. Cutis 84 Suppl. 4: 14-24.
49. Di Cesare A, Di Meglio P, Nestle FO (2009): The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol 129: 1339-1350.
50. Schottelius AJ, Moldawer LL, Dinarello CA, et al. (2004): Biology of tumor necrosis factor-α - implications for psoriasis. Exp Dermatol 13: 193-222.
51. Pietrzak AT, Zalewska A, Chodorowska G, et al. (2008): Cytokines and anticytokines in psoriasis. Clin Chim Acta 394: 7-21.
52. Gottlieb AB, Chamian F, Masud S, et al. (2005): TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J Immunol 175: 2721-2729.
53. Torti DC, Feldman SR (2007): Interleukin-12, interleukin-23, and psoriasis: current prospects. J Am Acad Dermatol 57: 1059-1068.